论文部分内容阅读
目的探讨阿仑膦酸钠联合注射用骨肽治疗骨质疏松症的临床效果。方法选择2013年1—12月收治的60例骨质疏松症患者作为研究对象,随机分为A组、B组、C组各20例。A组患者给予阿仑膦酸钠片+注射用骨肽+钙尔奇D治疗;B组患者给予阿仑膦酸钠片+钙尔奇D治疗;C组患者给予注射用骨肽+钙尔奇D治疗。3组患者均治疗6个月。比较患者治疗后临床效果及骨密度的变化情况。计量资料采用单因素方差分析,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果 A组治疗总有效率为95%,明显高于B组的65%和C组的60%,差异均有统计意义(均P<0.05)。治疗后A组、B组、C组骨密度变化率分别为(9.23±2.67)%、(7.56±2.34)%、(7.49±2.44)%,差异有统计学意义(P<0.05)。结论阿仑膦酸钠片联合注射液骨肽治疗骨质疏松症具有较好的临床效果及较高的安全性,值得进一步推广应用。
Objective To investigate the clinical efficacy of alendronate combined with bone peptide for the treatment of osteoporosis. Methods Sixty osteoporosis patients admitted from January to December in 2013 were randomly divided into group A, group B and group C, 20 cases each. A group of patients given alendronate sodium tablets + bone peptide injection + Calcium odd D treatment; B group were given alendronate sodium tablets + Calcium odd D treatment; C group patients given bone injection of bone peptide + Odd treatment. Three groups of patients were treated for 6 months. Compare the clinical effect of patients after treatment and changes in bone mineral density. Measurement data using one-way analysis of variance, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate in group A was 95%, which was significantly higher than 65% in group B and 60% in group C (all P <0.05). The change rates of bone mineral density in group A, group B and group C after treatment were (9.23 ± 2.67)%, (7.56 ± 2.34)% and (7.49 ± 2.44)%, respectively. The difference was statistically significant (P <0.05). Conclusion alendronate sodium tablets combined with injection of bone peptide in the treatment of osteoporosis has a good clinical effect and high safety, it is worth further promotion and application.